Generali Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Generali Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.53M	Sell	15,161 -139	-0.9%	-$61.6K	0.14%	147
2026 Q1	$6.83M	Sell	15,300 -3,238	-17%	-$1.51M	0.14%	143
2025 Q4	$8.4M	Sell	18,538 -5,031	-21%	-$2.17M	0.17%	118
2025 Q3	$9.23M	Buy	23,569 +6,942	+42%	+$2.9M	0.2%	104
2025 Q2	$7.4M	Sell	16,627 -1,705	-9%	-$786K	0.17%	125
2025 Q1	$8.89M	Sell	18,332 -4,529	-20%	-$2.11M	0.22%	102
2024 Q4	$9.21M	Buy	+22,861	New	+$10.6M	0.24%	89

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Generali Asset Management's VRTX Position: Q2 2026 in Review

Generali Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.91% in Q2 2026, selling an estimated $61.6K and leaving 15,161 shares worth $7.53M. The position accounts for 0.14% of the portfolio, ranked #147.

Generali Asset Management first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $9.23M in Q3 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Generali Asset Management held 15,161 shares of Vertex Pharmaceuticals worth $7.53M as of Q2 2026.
Generali Asset Management sold 139 Vertex Pharmaceuticals shares in Q2 2026, an estimated $61.6K.
Vertex Pharmaceuticals made up 0.14% of Generali Asset Management's portfolio in Q2 2026, its #147 holding.
Generali Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Generali Asset Management's Vertex Pharmaceuticals position peaked at $9.23M in Q3 2025.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Generali Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.